Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.

@article{Thompson2016EliminatingMR,
  title={Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.},
  author={Philip A Thompson and William G Wierda},
  journal={Blood},
  year={2016},
  volume={127 3},
  pages={279-86}
}
Deep remission and prolonged disease-free survival can be achieved with first-line chemoimmunotherapy (CIT), such as combined fludarabine, cyclophosphamide, and rituximab, in the majority of patients with chronic lymphocytic leukemia (CLL). More modest results are reported with less intense regimens like obinutuzumab plus chlorambucil. Clinical assessment has limited sensitivity in detecting residual disease responsible for subsequent relapse, even including morphologic bone marrow (BM… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS
18 Citations
72 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 72 references

Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHVmutated chronic lymphocytic leukemia [published online ahead of print

  • PA Thompson, CS Tam, SM O’Brien
  • Blood. doi:10.1182/blood-2015-09-667675
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…